AZD5634 is a drug that blocks the sodium channel in airway cells. By blocking this channel, the drug may help to rehydrate mucus in the lungs, making it thinner and easier to clear.
A Phase 1b study to test safety and effectiveness of AZD5634 in adults with CF will begin soon.
Advanced to end of Phase One.
This program is sponsored by Astra Zeneca. This program is being conducted within CFFT's Therapeutic Development Network (TDN).
Contact us about AZD5634 >